Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zoë Denis

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Technology in Cancer Research & Treatment|April 3, 2026
Fully Automated Stain Quantification Framework for IHC Whole Slide Images in Breast CancerTuo Yin, Frédéric Lifrange, Zoë Denis, et al.
Nature Medicine|June 25, 2026
Neoadjuvant stereotactic body radiation therapy with durvalumab and oleclumab in ER<sup>+</sup>HER2<sup>-</sup> breast cancer: a randomized phase 2 trialAlex De Caluwé, Isabelle Desmoulins, Kim Cao, et al.
Nature Communications|November 3, 2023
Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trialLaurence Buisseret, Delphine Loirat, Philippe Aftimos, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Technology in Cancer Research & Treatment|April 3, 2026
Fully Automated Stain Quantification Framework for IHC Whole Slide Images in Breast CancerTuo Yin, Frédéric Lifrange, Zoë Denis, et al.
Nature Medicine|June 25, 2026
Neoadjuvant stereotactic body radiation therapy with durvalumab and oleclumab in ER<sup>+</sup>HER2<sup>-</sup> breast cancer: a randomized phase 2 trialAlex De Caluwé, Isabelle Desmoulins, Kim Cao, et al.
Nature Communications|November 3, 2023
Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trialLaurence Buisseret, Delphine Loirat, Philippe Aftimos, et al.
Pageof 1